Final participant treated in Phase 2 hay fever trial
Filed with ASX · · 2 pages · English
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Paradigm receives $1.34 million R&D tax incentive rebate
- Paradigm Update Ross River Virus Clinical Trial
- Quarterly Cashflow Report
- Recruitment complete in Paradigms hay fever clinical trial
- Paradigms hay fever clinical trial cleared to commence
Later from Paradigm Biopharmaceuticals
- Paradigm March Quarter Update & Appendix 4C
- Paradigm Government grant for Ross River virus research
- Paradigms preclinical hay fever trial published
- Paradigm Receives Ethics Approval for Ross River Trial
- Hay Fever Trial Update
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals